Ming-Yao Su

Ming-Yao Su

Auto-generated profile, based on publicly available information

Ming-Yao Su

Chang Gung Inflammatory Bowel Disease Center, Taoyuan, Taiwan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MSMing-Yao Su
Ming-Yao Su
To assess the long-term outcome of endoscopic hemorrhoid ligation (EHL) for the treatment of symptomatic internal hemorrhoids. A total of 759 consecutive patients (415 males and 344 females) were enrolled. Clinical presentations were rectal bleeding (593 patients) and mucosal prolapse (166 patients). All patients received EHL at outpatient clinics. Hemorrhoid severity was classified by Goligher's grading. The mean follow-up period was 55.4 mo (range, 45-92 mo). The number of band ligations averaged 2.35 in the first session for bleeding and 2.69 for prolapsed patients. Bleeding was controlled in 587 (98.0%) patients, while prolapse was reduced in 137 (82.5%) patients. After treatment, 93 patients experienced anal pain and 48 patients had mild bleeding. Patient subjective satisfaction was 93.6%. Repeat treatment or surgery was performed if symptoms were not relieved in the first session. In the bleeding group, the recurrence rate was 3.7% (22 patients) at 1 year, and 6.6% and 13.0% at 2 and 5 years. In the prolapsed group, the recurrence rate was 3.0%, 9.6% and 16.9% at 1, 2 and 5 years, respectively. EHL is an easy and well-tolerated procedure for the treatment of symptomatic internal hemorrhoids, with good long-term results.

1 June 2021 in Digestive and Liver Disease
Verified
Journal Article
Closed access
PYPai-Jui Yeh
Pai-Jui Yeh
Cheng-Hsun ChiuCheng-Hsun Chiu
Cheng-Hsun Chiu
MLMing-Wei Lai
Ming-Wei Lai
RWRen-Chin Wu
Ren-Chin Wu
CKChcia-Jung Kuo
Chcia-Jung Kuo
PLPuo-Hsien Le
Puo-Hsien Le

1 February 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
MMMing-Jung Meng
Ming-Jung Meng
CKChia-Jung Kuo
Chia-Jung Kuo
MLMing-Wei Lai
Ming-Wei Lai
Cheng-Hsun ChiuCheng-Hsun Chiu
Cheng-Hsun Chiu
MSMing-Yao Su
Ming-Yao Su
PLPuo-Hsien Le
Puo-Hsien Le
Background: Refractory inflammatory bowel disease (IBD) remains challenging despite the availability of various biologics. Advanced combination therapy (ACT) with biologics and Upadacitinib (UPA), a rapid-onset oral selective Janus kinase inhibitor, has shown promise in managing refractory IBD. However, its use in Asia has not been explored. This study aims to fill that gap by providing data from Taiwan. Materials and Methods: This retrospective study included refractory IBD patients who received ACT with biologics and UPA, followed up at the Chang Gung Inflammatory Bowel Disease Center from July 2020 to August 2024. Patients were assessed for clinical response and remission at weeks 4, 12, and 24. Safety profiles were monitored throughout the follow-up period to evaluate the risk of adverse events. Results: Sixteen refractory IBD patients were enrolled. The median disease duration was 4.5 years [IQR 2.25– 9.50]. The most common regimen was Ustekinumab plus UPA (63%). Clinical response rates at weeks 4, 12, and 24 were 88%, 83%, and 100%, respectively, while remission rates were 31%, 50%, and 80%. One patient (6.25%) experienced a minor adverse event (acne), with no major events like herpes zoster reactivation or major cardiac complications. Conclusion: This is the first study in Asia to demonstrate that UPA-based ACT is both effective and safe in treating refractory IBD. However, the limitations of this retrospective, single-center study with a relatively small sample size highlight the need for future larger-scale, multi-center prospective studies to confirm these findings, identify predictors of treatment response, and evaluate long-term outcomes.

13 November 2022 in Advances in Digestive Medicine
Verified
Journal Article
Closed access
PLPuo-Hsien Le
Puo-Hsien Le
RWRen-Chin Wu
Ren-Chin Wu
CCChien-Ming Chen
Chien-Ming Chen
CKChcia-Jung Kuo
Chcia-Jung Kuo
MSMing‐Yao Su
Ming‐Yao Su
Cheng-Hsun ChiuCheng-Hsun Chiu
Cheng-Hsun Chiu

18 March 2024 in Advances in Digestive Medicine
Verified
Journal Article
Closed access
PHPo‐Han Huang
Po‐Han Huang
WLWey‐Ran Lin
Wey‐Ran Lin
PLPuo-Hsien Le
Puo-Hsien Le
CLCheng‐Yu Lin
Cheng‐Yu Lin
CCChun‐Wei Chen
Chun‐Wei Chen
Chia Jung KuoChia Jung Kuo
Chia Jung Kuo

29 July 2021 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MCMeng-Wu Chung
Meng-Wu Chung
CCChien-Ming Chen
Chien-Ming Chen
JHJun-Te Hsu
Jun-Te Hsu
RWRen-Chin Wu
Ren-Chin Wu
Cheng-Hsun ChiuCheng-Hsun Chiu
Cheng-Hsun Chiu
PLPuo-Hsien Le
Puo-Hsien Le
Background: Intestinal perforations and fistulas are common complications of Crohn’s disease. However, chronic perforation with peritoneal space to rectal and vaginal fistulas have not been previously reported. Case presentation: A 38-year-old female suffered from progressive lower abdominal pain, diarrhea and weight loss. Terminal ileal chronic perforation with intra-abdominal abscess, peritoneal space to rectal and vaginal fistulas were noted. The patient received surgical resection of the cecum and terminal ileum, and then vedolizumab treatment. Three months later, she had complete fistula closure, and her body mass index had increased from 13 to 22. Conclusion: Vedolizumab combined with stool diversion is effective at treating Crohn’s disease with chronic perforation and complex peritoneal space to rectal and vaginal fistulas.